{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T14:05:42Z","timestamp":1769090742291,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-025-04663-3","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T18:53:24Z","timestamp":1752519204000},"page":"189-199","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The efficacy and safety of enzalutamide in metastatic hormone-sensitive prostate cancer: a meta-analysis based on subgroups and reconstructed individual patient data"],"prefix":"10.1007","volume":"58","author":[{"given":"Fuxun","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhirong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuyan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pati-Alam","family":"Alisha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uzoamaka Adaobi","family":"Okoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"issue":"3","key":"4663_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"4663_CR2","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74(1):12\u201349","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"4663_CR3","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","volume":"36","author":"CE Kyriakopoulos","year":"2018","unstructured":"Kyriakopoulos CE, Chen YH, Carducci MA et al (2018) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol 36(11):1080\u20131087","journal-title":"J Clin Oncol"},{"issue":"6","key":"4663_CR4","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1001\/jamaoncol.2024.0591","volume":"10","author":"M Hussain","year":"2024","unstructured":"Hussain M, Fizazi K, Shore ND et al (2024) Metastatic hormone-sensitive prostate cancer and combination treatment outcomes: a review. JAMA Oncol 10(6):807\u2013820","journal-title":"JAMA Oncol"},{"issue":"1","key":"4663_CR5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.euo.2023.05.002","volume":"7","author":"J Dodkins","year":"2024","unstructured":"Dodkins J, Nossiter J, Cook A et al (2024) Does research from clinical trials in metastatic hormone-sensitive prostate cancer treatment translate into access to treatments for patients in the \u201cReal World\u201d? A systematic review. Eur Urol Oncol 7(1):14\u201324","journal-title":"Eur Urol Oncol"},{"key":"4663_CR6","doi-asserted-by":"crossref","unstructured":"Zhang F, Luo Z, Xue Q, et al (2025) The efficacy of abiraterone in metastatic hormone-sensitive prostate cancer: a stratified meta-analysis based on subgroups of low or high disease volume and reconstructed individual patient data. Expert Rev Anticancer Ther. Epub ahead of print.","DOI":"10.1080\/14737140.2025.2522981"},{"issue":"4","key":"4663_CR7","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.eururo.2025.01.010","volume":"87","author":"AA Azad","year":"2025","unstructured":"Azad AA, Kostos L, Agarwal N et al (2025) Combination therapies in locally advanced and metastatic hormone-sensitive prostate cancer. Eur Urol 87(4):455\u2013467","journal-title":"Eur Urol"},{"issue":"20","key":"4663_CR8","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1200\/JCO.20.03488","volume":"39","author":"KN Chi","year":"2021","unstructured":"Chi KN, Chowdhury S, Bjartell A et al (2021) Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol 39(20):2294\u20132303","journal-title":"J Clin Oncol"},{"issue":"12","key":"4663_CR9","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith MR, Hussain M, Saad F et al (2022) Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med 386(12):1132\u20131142","journal-title":"N Engl J Med"},{"issue":"36","key":"4663_CR10","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.1200\/JCO-24-01798","volume":"42","author":"F Saad","year":"2024","unstructured":"Saad F, Vjaters E, Shore N et al (2024) Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial. J Clin Oncol 42(36):4271\u20134281","journal-title":"J Clin Oncol"},{"issue":"11","key":"4663_CR11","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1080\/14737140.2024.2405103","volume":"24","author":"CD Miller","year":"2024","unstructured":"Miller CD, Likasitwatanakul P, Toye E et al (2024) Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment. Expert Rev Anticancer Ther 24(11):1085\u20131100","journal-title":"Expert Rev Anticancer Ther"},{"issue":"2","key":"4663_CR12","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis ID, Martin AJ, Stockler MR et al (2019) Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med 381(2):121\u2013131","journal-title":"N Engl J Med"},{"issue":"4","key":"4663_CR13","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S1470-2045(23)00063-3","volume":"24","author":"CJ Sweeney","year":"2023","unstructured":"Sweeney CJ, Martin AJ, Stockler MR et al (2023) Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. Lancet Oncol 24(4):323\u2013334","journal-title":"Lancet Oncol"},{"issue":"32","key":"4663_CR14","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP et al (2019) ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol 37(32):2974\u20132986","journal-title":"J Clin Oncol"},{"issue":"15","key":"4663_CR15","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1200\/JCO.22.00193","volume":"40","author":"AJ Armstrong","year":"2022","unstructured":"Armstrong AJ, Azad AA, Iguchi T et al (2022) Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol 40(15):1616\u20131622","journal-title":"J Clin Oncol"},{"issue":"2","key":"4663_CR16","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41391-021-00436-y","volume":"25","author":"AA Azad","year":"2022","unstructured":"Azad AA, Armstrong AJ, Alcaraz A et al (2022) Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk. Prostate Cancer Prostatic Dis 25(2):274\u2013282","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"4663_CR17","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.euo.2023.11.012","volume":"7","author":"F Gomez-Veiga","year":"2024","unstructured":"Gomez-Veiga F, Szmulewitz RZ, Holzbeierlein J et al (2024) Clinical outcomes of enzalutamide in metastatic hormone-sensitive prostate cancer in patients aged <75 and \u226575 years: ARCHES post hoc analysis. Eur Urol Oncol 7(4):860\u2013869","journal-title":"Eur Urol Oncol"},{"key":"4663_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"key":"4663_CR19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D et al (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16","journal-title":"Trials"},{"key":"4663_CR20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJ et al (2012) Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan\u2013Meier survival curves. BMC Med Res Methodol 12:9","journal-title":"BMC Med Res Methodol"},{"issue":"5","key":"4663_CR21","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.eururo.2023.06.012","volume":"85","author":"G Gandaglia","year":"2024","unstructured":"Gandaglia G, Pellegrino F, Golozar A et al (2024) Clinical characterization of patients diagnosed with prostate cancer and undergoing conservative management: a PIONEER analysis based on big data. Eur Urol 85(5):457\u2013465","journal-title":"Eur Urol"},{"issue":"6","key":"4663_CR22","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.euo.2022.04.007","volume":"5","author":"D Menges","year":"2022","unstructured":"Menges D, Yebyo HG, Sivec-Muniz S et al (2022) Treatments for metastatic hormone-sensitive prostate cancer: systematic review, network meta-analysis, and benefit-harm assessment. Eur Urol Oncol 5(6):605\u2013616","journal-title":"Eur Urol Oncol"},{"key":"4663_CR23","doi-asserted-by":"publisher","first-page":"100962","DOI":"10.1016\/j.drup.2023.100962","volume":"68","author":"M Cai","year":"2023","unstructured":"Cai M, Song XL, Li XA et al (2023) Current therapy and drug resistance in metastatic castration-resistant prostate cancer. Drug Resist Updat 68:100962","journal-title":"Drug Resist Updat"},{"issue":"20","key":"4663_CR24","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1200\/JCO.23.00723","volume":"41","author":"J Wala","year":"2023","unstructured":"Wala J, Nguyen P, Pomerantz M (2023) Early treatment intensification in metastatic hormone-sensitive prostate cancer. J Clin Oncol 41(20):3584\u20133590","journal-title":"J Clin Oncol"},{"key":"4663_CR25","first-page":"875","volume":"7","author":"J Semenas","year":"2013","unstructured":"Semenas J, Dizeyi N, Persson JL (2013) Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer. Drug Des Devel Ther 7:875\u2013881","journal-title":"Drug Des Devel Ther"},{"issue":"2","key":"4663_CR26","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41391-021-00395-4","volume":"25","author":"M Wenzel","year":"2022","unstructured":"Wenzel M, Nocera L, Coll\u00e0 Ruvolo C et al (2022) Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. Prostate Cancer Prostatic Dis 25(2):139\u2013148","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"4663_CR27","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1210\/endrev\/bnab002","volume":"42","author":"K Desai","year":"2021","unstructured":"Desai K, McManus JM, Sharifi N (2021) Hormonal therapy for prostate cancer. Endocr Rev 42(3):354\u2013373","journal-title":"Endocr Rev"},{"issue":"2","key":"4663_CR28","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.euo.2024.08.007","volume":"8","author":"M Wenzel","year":"2024","unstructured":"Wenzel M, Cano Garcia C, Humke C et al (2024) Prostate-specific antigen nadir and cancer-control outcomes in real-world apalutamide-treated metastatic hormone-sensitive prostate cancer patients: a single-center analysis. Eur Urol Oncol 8(2):364\u2013371","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"4663_CR29","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L et al (2017) Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 377(4):352\u2013360","journal-title":"N Engl J Med"},{"issue":"4","key":"4663_CR30","doi-asserted-by":"publisher","first-page":"402","DOI":"10.4103\/aja20242","volume":"26","author":"SS Wang","year":"2024","unstructured":"Wang SS, Bian XJ, Wu JL et al (2024) Network meta-analysis of combination strategies in metastatic hormone-sensitive prostate cancer. Asian J Androl 26(4):402\u2013408","journal-title":"Asian J Androl"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04663-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-025-04663-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04663-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T20:01:38Z","timestamp":1768161698000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-025-04663-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["4663"],"URL":"https:\/\/doi.org\/10.1007\/s11255-025-04663-3","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,14]]},"assertion":[{"value":"10 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}]}}